https://www.mssociety.org.uk/research/l ... ecruitment
MS-STAT2 is investigating whether cholesterol-lowering drug simvastatin slows disability progression in secondary progressive MS. It’s a phase 3 trial. So it’s the final, definitive stage of testing following positive smaller trials.
With recruitment finishing, we’re a step closer to knowing whether simvastatin could be the first treatment for people with progressive MS that protects nerves from damage in MS.
- Similar Topics
- Last post